A Safety Run-In And Phase II Study Evaluating The Efficacy, Safety, And Impact On The Tumor Microenvironment Of The Combination Of Tocilizumab, Atezolizumab, And Fractionated Stereotactic Radiotherapy In Recurrent Glioblastoma

Brief Summary

Type:
Brain Tumors / Neurologic Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04729959

Study #:
STUDY00148468

Start Date:
May 31, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04729959

View Complete Trial Details & Eligibility at ClinicalTrials.gov